/SBBP

SBBP Stock - Strongbridge Biopharma plc

Q: What is the analyst price target for SBBP?

Analyst price target information is not currently available for SBBP.

Q: What is SBBP's market cap?

Market capitalization information is not currently available for SBBP.

Healthcare|Biotechnology|NASDAQ

$2.00+1.52%

+$0.03 (+1.52%) • Apr 24

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.20

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SBBP

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2016

FY2017

FY2018

FY2019

FY2020

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.60

52W High$4.26

52W Low$1.85

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2020	FY2019	FY2018	FY2017	FY2016
Revenue	$30.73M	$21.71M	$18.03M	$7.05M	N/A
Gross Profit	$28.52M	$17.89M	$14.04M	$5.56M	N/A
Gross Margin	92.8%	82.4%	77.9%	79.0%	N/A
Operating Income	$-43,165,000	$-63,845,000	$-81,923,000	$-53,019,000	$-34,898,000
Net Income	$-45,075,000	$-49,451,000	$31.85M	$-113,483,000	$-48,597,000
Net Margin	-146.7%	-227.8%	176.7%	-1610.6%	N/A
EPS	$-0.80	$-0.89	$0.64	$-3.11	$-2.26

Company Overview

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.

Visit Website

Earnings History & Surprises

SBBP

Beat Rate

63%

Last 19 quarters

Avg Surprise

+10.0%

EPS vs Estimate

Beats / Misses

12/7

Last 12 quarters

Latest EPS

$-0.07

Q3 2021

EPS Surprise History

Q4 19

+7.4%

$-0.25vs$-0.27

Q1 20

+3.8%

$-0.25vs$-0.26

Q2 20

+13.6%

$-0.19vs$-0.22

Q3 20

+42.9%

$-0.12vs$-0.21

Q4 20

+14.3%

$-0.12vs$-0.14

Q1 21

+8.3%

$-0.11vs$-0.12

Q2 21

-10.0%

$-0.11vs$-0.10

Q3 21

+30.0%

$-0.07vs$-0.10

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2021	Aug 5, 2021	$-0.10	$-0.07	+30.0%	✓ BEAT
Q2 2021	May 12, 2021	$-0.10	$-0.11	-10.0%	✗ MISS
Q1 2021	Mar 3, 2021	$-0.12	$-0.11	+8.3%	✓ BEAT
Q4 2020	Oct 29, 2020	$-0.14	$-0.12	+14.3%	✓ BEAT
Q3 2020	Aug 4, 2020	$-0.21	$-0.12	+42.9%	✓ BEAT
Q2 2020	May 6, 2020	$-0.22	$-0.19	+13.6%	✓ BEAT
Q1 2020	Feb 25, 2020	$-0.26	$-0.25	+3.8%	✓ BEAT
Q4 2019	Nov 7, 2019	$-0.27	$-0.25	+7.4%	✓ BEAT
Q3 2019	Jul 31, 2019	$-0.34	$-0.24	+29.4%	✓ BEAT
Q2 2019	May 1, 2019	$-0.37	$-0.25	+32.4%	✓ BEAT
Q1 2019	Feb 26, 2019	$-0.49	$1.64	+434.7%	✓ BEAT
Q4 2018	Oct 31, 2018	$-0.38	$-0.44	-15.8%	✗ MISS
Q3 2018	Aug 8, 2018	$-0.47	$-0.06	+87.2%	✓ BEAT
Q2 2018	May 10, 2018	$-0.39	$-0.66	-69.2%	✗ MISS
Q1 2018	Mar 12, 2018	$-0.32	$-0.47	-46.9%	✗ MISS
Q4 2017	Nov 14, 2017	$-0.38	$-0.98	-157.9%	✗ MISS
Q3 2017	Aug 7, 2017	$-0.34	$-0.86	-152.9%	✗ MISS
Q2 2017	May 16, 2017	$-0.49	$-0.83	-69.4%	✗ MISS
Q4 2016	Dec 31, 2016	—	$-0.75	—	—
Q4 2016	Dec 23, 2016	$-0.39	$-0.36	+7.7%	✓ BEAT

Frequently Asked Questions about SBBP

What is SBBP's current stock price?

Strongbridge Biopharma plc (SBBP) is currently trading at $2.00 per share. The stock has moved +1.52% today.

What is the analyst price target for SBBP?

No analyst price targets are currently available for this stock.

What sector is Strongbridge Biopharma plc in?

Strongbridge Biopharma plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is SBBP's market cap?

Strongbridge Biopharma plc has a market capitalization of N/A, making it a small-cap company.

Does SBBP pay dividends?

No, Strongbridge Biopharma plc does not currently pay a dividend to shareholders.